There are great companies, and there are companies that do great things in the marketplace…and for your health.
The latter is the kind of company I'm talking about here.
And it's the reason why its stock has soared and will continue to soar as the years roll on….
Twenty Years of Coverage Helped Me Isolate This Pick
This isn't a story I just came upon while running my screens one night. I've been following developments involving multiple sclerosis (MS) therapies for more than 20 years. It all goes back to a four-part series I wrote while working as a biotech analyst at the Oakland Tribune.
My series focused on the release of Betaseron, a genetically altered protein designed to lessen the number and severity of MS attacks.
This was in the early days of the biotech revolution, which has not only spawned some of the greatest medical discoveries but some of the greatest wealth-creating opportunities.
This drug had plenty of critics who complained about serious side effects like insomnia and depression.
However, it also was the first FDA-approved drug found to alter the course of this debilitating autoimmune disease – one known to cause severe inflammation that can impact walking, vision, and speech. It can severely shorten its victims' life expectancy as well as their ability to enjoy their remaining years.
Approved in 1993, the drug is still on the market today and is sold by a unit of Bayer AG (OTCMKTS ADR: BAYRY). It ranks as the interferon, a human protein, with the longest record of clinical effectiveness and safety.
But in recent years, there's another biotech leader that has helped revolutionize MS treatment. So much so that its portfolio of approved MS drugs has become a major catalyst driving the stock up 632% in the past five years.
What's more, this very same biotech – one of the first to emerge in the 1970s – is now focusing its attention on another insidious and even more pervasive disease: Alzheimer's.
The company also has a number of well-regarded drugs in the marketplace that have helped patients with B-cell non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia, and hemophilia.
A Company on the Move
I'm talking about Biogen Inc. (Nasdaq: BIIB), a global big-cap player that operates at the forefront of life sciences as though it were still a small, clinical-stage firm.
Consider that earlier this year the company announced it was partnering with Google Inc. (Nasdaq: GOOG, GOOGL). Biogen and Google's futuristic X labs are using sensors, software, and data analysis tools to explore why MS progresses differently in each patient.
Earlier, Biogen had initiated a project with Fitbit, using the company's activity trackers to gather data on MS patients. The Google partnership is an extension of that kind of thinking – using sensors to track the real-time medical data and also analyze all the Big Data to look for clues in treating and getting ahead of MS.
This digital health approach also has huge implications for understanding all sorts of complex diseases, from cancer to Parkinson's. It highlights the kind of creative partnering that has made Biogen such a force in the industry.
And as you can see from the continued advance in Biogen's stock, the focus on innovation is richly rewarding the company's investors.
It's Not Too Expensive and Here's Why
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.